| pubmed-article:10720913 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C0497209 | lld:lifeskim |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C1136254 | lld:lifeskim |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:10720913 | lifeskim:mentions | umls-concept:C0067899 | lld:lifeskim |
| pubmed-article:10720913 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10720913 | pubmed:dateCreated | 2000-5-8 | lld:pubmed |
| pubmed-article:10720913 | pubmed:abstractText | N-Chlorotaurine (NCT) is an endogenous microbicidal oxidant. This open pilot study (phase IIa) with 9 patients was done to gain first knowledge on the tolerance of NCT in infectious conjunctivitis. By application of 1% NCT 5 times a day, no adverse effects could be observed. All 6 subjects with bacterial conjunctivitis were cured within 3-5 days. Two subjects with epidemic keratoconjunctivitis were treated for 7-10 days and 1 subject with herpes simplex blepharitis for 3 days with no rapid improvement but probable mitigation of inflammation. Therefore, NCT seems to be useful in the treatment of infectious conjunctivitis, and further investigation on its therapeutic efficacy is suggested. | lld:pubmed |
| pubmed-article:10720913 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10720913 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10720913 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10720913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10720913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10720913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10720913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10720913 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10720913 | pubmed:issn | 0030-3755 | lld:pubmed |
| pubmed-article:10720913 | pubmed:author | pubmed-author:GottardiWW | lld:pubmed |
| pubmed-article:10720913 | pubmed:author | pubmed-author:UlmerHH | lld:pubmed |
| pubmed-article:10720913 | pubmed:author | pubmed-author:NagoNN | lld:pubmed |
| pubmed-article:10720913 | pubmed:author | pubmed-author:TeuchnerBB | lld:pubmed |
| pubmed-article:10720913 | pubmed:author | pubmed-author:PöttingerEE | lld:pubmed |
| pubmed-article:10720913 | pubmed:copyrightInfo | Copyright 2000 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:10720913 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10720913 | pubmed:volume | 214 | lld:pubmed |
| pubmed-article:10720913 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10720913 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10720913 | pubmed:pagination | 111-4 | lld:pubmed |
| pubmed-article:10720913 | pubmed:dateRevised | 2007-9-17 | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:meshHeading | pubmed-meshheading:10720913... | lld:pubmed |
| pubmed-article:10720913 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10720913 | pubmed:articleTitle | Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis - a phase II pilot study. | lld:pubmed |
| pubmed-article:10720913 | pubmed:affiliation | Institute for Hygiene of the Leopold Franzens University of Innsbruck, Austria. waldemar.gottardi@uibk.ac.at | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10720913 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10720913 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10720913 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10720913 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10720913 | lld:pubmed |
